Visualitzant O - Articles científics per títol

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Lozano, Rebeca; Lorente, David; Aragon, Isabel M.; Romero-Laorden, Nuria; Nombela, Paz; Mateo Valderrama, Joaquim (MDPI, 2021-05)

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites

Sabarinathan, Radhakrishnan; Gonzalez-Perez, Abel; Lopez-Bigas, Nuria; Frigola Rissech, Joan (Oxford University Press, 2021-01-25)

VHrare study: Prevalence, clinical features and management of severe rare bleeding disorders in a large cohort

Martinez Garcia, Maria Fernanda; Corrales Insa, Irene; Fernández-Caballero, Mariana; Ramírez Orihuela, Lorena; Cortina Giner, Vicente; Comes Fernandez, Natalia; Juarez-Gimenez, Juan Carlos; Benítez Hidalgo, Olga (Wiley, 2023-05)

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

Feliu, Jaime; Guasch, Inmaculada; Alonso-Orduna, Vicente; López Gil, Carlos; Capdevila Castillon, Jaume; Garcia-Carbonero, Rocio (Wiley, 2020-02)

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

Ligero, Marta; El Nahhas, Omar; SANSANO, IRENE; Mauchanski, Siarhei; Serna, Garazi; Viaplana, Cristina; Toledo, Rodrigo; Dienstmann, Rodrigo; Ramon y Cajal, Santiago; GARRALDA, Elena; Nuciforo, Paolo; Perez-Lopez, Raquel (American Association for Cancer Research, 2024-01)

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

Cosentino, Giulia; Cataldo, Alessandra; Plantamura, Ilaria; Nuciforo, Paolo Giovanni; Ciniselli, Chiara Maura; Pizzamiglio, Sara; De Cecco, Loris (Wiley, 2022-01)

What is the status of immunotherapy in thyroid neoplasms?

Garcia Alvarez, Alejandro; Hernando Cubero, Jorge; Carmona Alonso, Ana; Capdevila Castillon, Jaume (Frontiers Media, 2022-08-05)

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

Partridge, Ann H.; Niman, Samuel M.; Ruggeri, Monica; Peccatori, Fedro A.; Azim Jr., Hatem A.; Colleoni, Marco; Saura Manich, Cristina (Elsevier, 2021-10)

Young oncologists' perspective on the role and future of the clinician-scientist in oncology

Lim, Kok Haw Jonathan; Westphalen, Benedikt; Berghoff, Anna Sophie; Cardone, Claudia; Connolly, E. A.; Guven, Deniz Can; Mateo, Joaquin (Elsevier, 2023-08-31)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites

VHrare study: Prevalence, clinical features and management of severe rare bleeding disorders in a large cohort

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

What is the status of immunotherapy in thyroid neoplasms?

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

Young oncologists' perspective on the role and future of the clinician-scientist in oncology

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients ﻿

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites ﻿

VHrare study: Prevalence, clinical features and management of severe rare bleeding disorders in a large cohort ﻿

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02) ﻿

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression ﻿

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study ﻿

What is the status of immunotherapy in thyroid neoplasms? ﻿

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy ﻿

Young oncologists' perspective on the role and future of the clinician-scientist in oncology ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites

VHrare study: Prevalence, clinical features and management of severe rare bleeding disorders in a large cohort

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

What is the status of immunotherapy in thyroid neoplasms?

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy

Young oncologists' perspective on the role and future of the clinician-scientist in oncology